Verkazia (Cyclosporine) Patent Expiration, LOE Window & CMS Spending

Verkazia (Cyclosporine) by Harrow Eye: FDA Orange Book LOE 2029-06-02, 6 AB generics, $1.9M 2024 CMS Part D & Medicaid spend, and 1 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorHarrow Eye
FDA Application & PathwayN214965 (NDA)
Exclusivity / Cliff HorizonNear-Term Cliff (2028-2030)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2029-06-02
Orange Book Patents (*PED Extensions)7 patents (0 *PED)
Active AB-Rated Generic Competitors6
2024 CMS Total Public Spend$1.9M
2024 Medicare Part D Spend$260K
2024 Medicaid Spend$1.6M
Reported Wholesale Price Change (CA SB 17)1 WAC filings (max 25.0% 2-yr change)